Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by All Cardiff Authors

[up] Up a level
Number of items: 11.

Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia ORCID: https://orcid.org/0000-0003-3758-1892, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 and Mahajna, Jamal 2021. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K. Annals of Hematology 100 , pp. 2023-2029. 10.1007/s00277-020-04357-z
file

Mian, Afsar A., Baumann, Ines, Liebermann, Marcus, Grebien, Florian, Superti-Furga, Giulio, Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811, Ottmann, Oliver G. ORCID: https://orcid.org/0000-0001-9559-1330 and Hantschel, Oliver 2019. The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis. Leukemia 33 , pp. 2319-2323. 10.1038/s41375-019-0468-y
file

Legut, Mateusz, Dolton, Garry, Mian, Afsar, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330 and Sewell, Andrew ORCID: https://orcid.org/0000-0003-3194-3135 2018. CRISPR-mediated TCR replacement generates superior anticancer transgenic T-cells. Blood 131 (3) , pp. 311-322. 10.1182/blood-2017-05-787598
file

Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia ORCID: https://orcid.org/0000-0003-3758-1892, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 and Mian, Afsar 2016. BCR: a new target in resistance mediated by BCR/ABL-315I? Genes & Cancer 7 (1-2) , pp. 36-46.

Oancea, Claudia, Rüster, Brigitte, Brill, Boris, Roos, Jessica, Heinssmann, Maria, Bug, Gesine, Mian, Afsar Ali, Guillen, Nathalie Andrea, Kornblau, Steven M., Henschler, Reinhard and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 2014. STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML. Genes & Cancer 5 (11-12) , pp. 378-392. 10.18632/genesandcancer.39

Khateb, Mamduh, Ruimi, Nili, Khamisie, Hazem, Najajreh, Yousef, Mian, Afsar, Metodieva, Anna, Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 and Mahajna, Jamal 2012. Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. BMC Cancer 12 , 563. 10.1186/1471-2407-12-563

Mian, Afsar Ali, Metodieva, Anna, Badura, Susanne, Khateb, Mamduh, Ruimi, Nili, Najajreh, Yousef, Ottmann, Oliver Gerhard ORCID: https://orcid.org/0000-0001-9559-1330, Mahajna, Jamal and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 2012. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer 12 (411) 10.1186/1471-2407-12-411

Mian, Afsar A., Metodieva, Anna, Najajreh, Yousef, Ottmann, Oliver G. ORCID: https://orcid.org/0000-0001-9559-1330, Mahajna, Jamal and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 2012. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica 97 (2) 10.3324/haematol.2011.047191

Mian, A A, Oancea, C, Zhao, Z, Ottmann, O G ORCID: https://orcid.org/0000-0001-9559-1330 and Ruthardt, M ORCID: https://orcid.org/0000-0003-1021-3811 2009. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia 23 , 2242–2247. 10.1038/leu.2009.194

Mian, A A, Schüll, M, Zhao, Z, Oancea, C, Hundertmark, A, Beissert, T, Ottmann, O G ORCID: https://orcid.org/0000-0001-9559-1330 and Ruthardt, M ORCID: https://orcid.org/0000-0003-1021-3811 2009. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 23 , 1614–1621. 10.1038/leu.2009.69

Beissert, Tim, Hundertmark, Alena, Kaburova, Velina, Travaglini, Lorena, Mian, Afsar A., Nervi, Clara and Ruthardt, Martin ORCID: https://orcid.org/0000-0003-1021-3811 2008. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. International Journal of Cancer 122 (12) , pp. 2744-2752. 10.1002/ijc.23467

This list was generated on Tue Apr 15 08:45:31 2025 BST.


Maintained by Cardiff University Information Services